Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Echo Therapeutics Inc. (ECTE : OTC)
 
 • Company Description   
Echo Therapeutics, Inc., a medical device and specialty pharmaceutical company, develops a non-invasive and wireless transdermal continuous glucose monitoring system for people with diabetes and for use in hospital critical care units in the United States. Its Symphony transdermal continuous glucose monitoring System is a non-invasive, wireless, designed to provide reliable, on-demand blood glucose data conveniently, continuously and cost-effectively. The company is based in Franklin, Massachusetts.

Number of Employees:

 
 • Price / Volume Information   
Yesterday's Closing Price: $ Daily Weekly Monthly
20 Day Moving Average: shares
Shares Outstanding: (millions)
Market Capitalization: $ (millions)
Beta:
52 Week High: $0.05
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week % %
12 Week % %
Year To Date % %
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
99 WOOD AVENUE SOUTH SUITE 302
-
ISELIN,NJ 08830
USA
ph: 732-549-0128
fax: 215-717-4109
colimpio@echotx.com http://www.echotx.com
 
 • General Corporate Information   
Officers
Michael M. Goldberg - Chairman of the Board
Scott W. Hollander - President; Chief Executive Officer
Alan W. Schoenbart - Chief Financial Officer
Shepard M. Goldberg - Director
Elazer R. Edelman - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED INSTRUMENTS
Sector: Medical
CUSIP: 27876L206
SIC: 3845
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: -
Next Expected EPS Date: -
Share - Related Items
Shares Outstanding:
Most Recent Split Date: 6.00 (0.10:1)
Beta:
Market Capitalization: $ (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: %
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: -  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -
12/31/24 - -
Current Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Quick Ratio
06/30/25 - -
03/31/25 - -
12/31/24 - -
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Pre-Tax Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -
Book Value
06/30/25 - -
03/31/25 - -
12/31/24 - -
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - -
 

Powered by Zacks Investment Research ©